0 0
0 0

References-Blog-Related

Posted on 4 May 2021 by Dr. Rodney Lopez MBBS ( USyd ) GradCertNutriMed (RMIT)
Category:
  1. Grindler, N.M., Vanderlinden, L., Karthikraj, R., Kannan, K., Teal, S., Polotsky, A.J., Powell, T.L., Yang, I.V. and Jansson, T., 2018. Exposure to phthalate, an endocrine disrupting chemical, alters the first trimester placental methylome and transcriptome in women. Scientific reports, 8(1), p.6086.
  2. Signorile, P.G. and Baldi, A., 2010. Endometriosis: new concepts in the pathogenesis. The international journal of biochemistry & cell biology, 42(6), pp.778-780.
  3. Louis, G.M.B., Peterson, C.M., Chen, Z., Hediger, M.L., Croughan, M.S., Sundaram, R., Stanford, J.B., Fujimoto, V.Y., Varner, M.W., Giudice, L.C. and Kennedy, A., 2012. Perfluorochemicals and Endometriosis The ENDO Study. Epidemiology (Cambridge, Mass.), 23(6), p.799.
  4. Kwa, M., Plottel, C.S., Blaser, M.J. and Adams, S., 2016. The intestinal microbiome and estrogen receptor–positive female breast cancer. JNCI: Journal of the National Cancer Institute, 108(8).
  5. Walaszek, Z., 1990. Potential use of D-glucaric acid derivatives in cancer prevention. Cancer letters, 54(1-2), pp.1-8.
  6. Upson, K., Sathyanarayana, S., De Roos, A.J., Thompson, M.L., Scholes, D., Dills, R. and Holt, V.L., 2013. Phthalates and risk of endometriosis. Environmental research, 126, pp.91-97.
  7. Hapangama, D.K., Kamal, A.M. and Bulmer, J.N., 2014. Estrogen receptor β: the guardian of the endometrium. Human reproduction update, 21(2), pp.174-193.
  8. McCarty, M.F., 2006. Isoflavones made simple–genistein’s agonist activity for the beta-type estrogen receptor mediates their health benefits. Medical hypotheses, 66(6), pp.1093-1114.
  9. Corrales, J., Kristofco, L.A., Steele, W.B., Yates, B.S., Breed, C.S., Williams, E.S. and Brooks, B.W., 2015. Global assessment of bisphenol A in the environment: review and analysis of its occurrence and bioaccumulation. Dose-Response, 13(3), p.1559325815598308.
  10. Parazzini, F., Viganò, P., Candiani, M. and Fedele, L., 2013. Diet and endometriosis risk: a literature review. Reproductive Biomedicine Online, 26(4), pp.323-336.
  11. Missmer, S.A., Chavarro, J.E., Malspeis, S., Bertone-Johnson, E.R., Hornstein, M.D., Spiegelman, D., Barbieri, R.L., Willett, W.C. and Hankinson, S.E., 2010. A prospective study of dietary fat consumption and endometriosis risk. Human Reproduction, 25(6), pp.1528-1535.
  12. Zeisel, S.H. and Da Costa, K.A., 2009. Choline: an essential nutrient for public health. Nutrition reviews, 67(11), pp.615-623.
  13. Brand-Miller, J.C., Atkinson, F.S., Gahler, R.J., Kacinik, V., Lyon, M.R. and Wood, S., 2010. Effects of PGX, a novel functional fibre, on acute and delayed postprandial glycaemia. European journal of clinical nutrition, 64(12), p.1488.
  14. Porpora, M.G., Brunelli, R., Costa, G., Imperiale, L., Krasnowska, E.K., Lundeberg, T., Nofroni, I., Piccioni, M.G., Pittaluga, E., Ticino, A. and Parasassi, T., 2013. A promise in the treatment of endometriosis: an observational cohort study on ovarian endometrioma reduction by N-acetylcysteine. Evidence-based Complementary and Alternative Medicine, 2013.
  15. Dull, A.M., Moga, M.A., Dimienescu, O.G., Sechel, G., Burtea, V. and Anastasiu, C.V., 2019. Therapeutic Approaches of Resveratrol on Endometriosis via Anti-Inflammatory and Anti-Angiogenic Pathways. Molecules, 24(4), p.667.
  16.  Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1246-1252
  17. Bulun, S.E., Fang, Z., Imir, G., Gurates, B., Tamura, M., Yilmaz, B., Langoi, D., Amin, S., Yang, S. and Deb, S., 2004, January. Aromatase and endometriosis. In Seminars in reproductive medicine (Vol. 22, No. 01, pp. 45-50). Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
  18. Lin, Y.H., Chen, Y.H., Chang, H.Y., Au, H.K., Tzeng, C.R. and Huang, Y.H., 2018. Chronic niche inflammation in endometriosis-associated infertility: current understanding and future therapeutic strategies. International journal of molecular sciences, 19(8), p.2385.
  19. Zhao, Y., Gong, P., Chen, Y., Nwachukwu, J.C., Srinivasan, S., Ko, C., Bagchi, M.K., Taylor, R.N., Korach, K.S., Nettles, K.W. and Katzenellenbogen, J.A., 2015. Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Science translational medicine, 7(271), pp.271ra9-271ra9.
  20. Ross, R. G., et al. (2013). “Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk.” American Journal of Psychiatry 170(3): 290-298.
  21. Zeisel, S. H. (2004). “Nutritional importance of choline for brain development.” Journal of the American College of Nutrition 23(suppl 6): 621S-626S.
  22. Salway, J. (2006). Medical biochemistry at a glance, Wiley-Blackwell.
  23. Margioris, A. N. (2009). “Fatty acids and postprandial inflammation.” Current Opinion in Clinical Nutrition & Metabolic Care 12(2): 129.
  24. Raubenheimer, D. and Simpson, S., 2020. Eat Like the Animals: What Nature Teaches Us about the Science of Healthy Eating. Houghton Mifflin.
  25. Pezzato, E., Sartor, L., Dell’Aica, I., Dittadi, R., Gion, M., Belluco, C., Lise, M. and Garbisa, S., 2004. Prostate carcinoma and green tea: PSA?triggered basement membrane degradation and MMP?2 activation are inhibited by (−) epigallocatechin?3?gallate. International Journal of Cancer, 112(5), pp.787-792.
  26. Niu, Y., Yeh, S., Miyamoto, H., Li, G., Altuwaijri, S., Yuan, J., Han, R., Ma, T., Kuo, H.C. and Chang, C., 2008. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer research, 68(17), pp.7110-7119.
  27. Dobbs, R.W., Malhotra, N.R., Greenwald, D.T., Wang, A.Y., Prins, G.S. and Abern, M.R., 2019. Estrogens and prostate cancer. Prostate cancer and prostatic diseases, 22(2), pp.185-194.
  28. Jahn, J.L., Giovannucci, E.L. and Stampfer, M.J., 2015. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate?specific Antigen?era. International journal of cancer, 137(12), pp.2795-2802.
  29. Billis, A. (1986). “Latent carcinoma and atypical lesions of prostate An autopsy study.” Urology 28(4): 324-329.
  30. Simopoulos, A. P. and L. Sidossis (2000). “What is so special about the traditional diet of Greece.” Mediterranean Diets. World Rev Nutr Diet 87: 24-42.
  31. Meyer, B.J., Mann, N.J., Lewis, J.L., Milligan, G.C., Sinclair, A.J. and Howe, P.R., 2003. Dietary intakes and food sources of omega?6 and omega?3 polyunsaturated fatty acids. Lipids, 38(4), pp.391-398.
  32. Thomas, R., Williams, M., Sharma, H., Chaudry, A. and Bellamy, P., 2014. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the UK NCRN Pomi-T study. Prostate cancer and prostatic diseases, 17(2), pp.180-186.
  33. Korkmaz, M., Avc?, C.B., Gunduz, C., Aygunes, D. and Erbaykent-Tepedelen, B., 2014. Disodium pentaborate decahydrate (DPD) induced apoptosis by decreasing hTERT enzyme activity and disrupting F-actin organization of prostate cancer cells. Tumor Biology, 35(2), pp.1531-1538.
  34. Nielsen, F.H. and Meacham, S.L., 2011. Growing evidence for human health benefits of boron. Journal of Evidence-Based Complementary & Alternative Medicine, 16(3), pp.169-180.
  35. Scorei, I.R., 2011. Boron compounds in the breast cancer cells chemoprevention and chemotherapy (p. 540). ISBN 978-953-307-776-5, Hard Cover, InTech Publication.
  36. Pizzorno, L., 2015. Nothing boring about boron. Integrative Medicine: A Clinician’s Journal, 14(4), p.35.
  37. Dobbs, R.W., Malhotra, N.R., Greenwald, D.T., Wang, A.Y., Prins, G.S. and Abern, M.R., 2019. Estrogens and prostate cancer. Prostate cancer and prostatic diseases, 22(2), pp.185-194.
  38. Melnik, B. C., et al. (2011). “Over-stimulation of insulin/IGF-1 signaling by western diet may promote diseases of civilization: lessons learnt from laron syndrome.” Nutrition & Metabolism 8(1): 41.
  39. Gupta, S., Srivastava, M., Ahmad, N., Sakamoto, K., Bostwick, D.G. and Mukhtar, H., 2001. Lipoxygenase?5 is overexpressed in prostate adenocarcinoma. Cancer, 91(4), pp.737-743.
  40. Altuwaijri, S., 2012. Role of prostate specific antigen (PSA) in pathogenesis of prostate cancer.
  41. Anand, P., Kunnumakara, A.B., Sundaram, C., Harikumar, K.B., Tharakan, S.T., Lai, O.S., Sung, B. and Aggarwal, B.B., 2008. Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical research, 25(9), pp.2097-2116.
  42. Sinclair, D.A. and LaPlante, M.D., 2019. Lifespan: Why We Age—and Why We Don’t Have To. Atria Books.
  43. Dobbs, R.W., Malhotra, N.R., Greenwald, D.T., Wang, A.Y., Prins, G.S. and Abern, M.R., 2019. Estrogens and prostate cancer. Prostate cancer and prostatic diseases, 22(2), pp.185-194.
  44. Stix, G. (2007). “A Malignant Flame.” Scientific American Magazine 297(1): 60-67.
  45. Awolade, P., Cele, N., Kerru, N., Gummidi, L., Oluwakemi, E. and Singh, P., 2020. Therapeutic significance of β-glucuronidase activity and its inhibitors: A review. European journal of medicinal chemistry, 187, p.111921.
  46. Hu, K., Callen, D.F., Li, J. and Zheng, H., 2018. Circulating vitamin D and overall survival in breast cancer patients: a dose-response meta-analysis of cohort studies. Integrative cancer therapies, 17(2), pp.217-225.
  47. Hu, N., Li, Y., Zhao, Y., Wang, Q., You, J.C., Zhang, X.D. and Ye, L.H., 2011. A novel positive feedback loop involving FASN/p-ERK1/2/5-LOX/LTB4/FASN sustains high growth of breast cancer cells. Acta Pharmacologica Sinica, 32(7), pp.921-929.
  48. Bishnoi, M., Patil, C.S., Kumar, A. and Kulkarni, S.K., 2005. Analgesic activity of acetyl-11-keto-beta-boswellic acid, a 5-lipoxygenase-enzyme inhibitor. Indian journal of pharmacology, 37(4), p.255.
  49. Emond, J.A., Pierce, J.P., Natarajan, L., Gapuz, L.R., Nguyen, J., Parker, B.A., Varki, N.M. and Patterson, R.E., 2014. Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGFI receptor. Cancer Epidemiology and Prevention Biomarkers, 23(7), pp.1273-1279.
  50. Sieri, S., Pala, V., Brighenti, F., Pellegrini, N., Muti, P., Micheli, A., Evangelista, A., Grioni, S., Contiero, P., Berrino, F. and Krogh, V., 2007. Dietary glycemic index, glycemic load, and the risk of breast cancer in an Italian prospective cohort study. The American journal of clinical nutrition, 86(4), pp.1160-1166.
  51. Orgel, E. and Mittelman, S.D., 2013. The links between insulin resistance, diabetes, and cancer. Current diabetes reports, 13(2), pp.213-222.
  52. Risbridger, G.P., Davis, I.D., Birrell, S.N. and Tilley, W.D., 2010. Breast and prostate cancer: more similar than different. Nature Reviews Cancer, 10(3), pp.205-212.
  53. LeBeau, A.M., Kostova, M., Craik, C.S. and Denmeade, S.R., 2010. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biological chemistry, 391(4), pp.333-343.
  54. Ames, B. N. (2006). “Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage.” Proceedings of the National Academy of Sciences 103(47): 17589-17594.
  55. Middleton, P., Gomersall, J.C., Gould, J.F., Shepherd, E., Olsen, S.F. and Makrides, M., 2019. Omega-3 Fatty Acid Addition During Pregnancy. Obstetrical & Gynecological Survey, 74(4), pp.189-191.
  56. Farquhar, C.M., 2000. Endometriosis. Bmj, 320(7247), pp.1449-1452.
  57. Evans, W.C., 2002. Trease and Evans. Pharmacognosy, 9th Edition published by Saunders Elsevier, pp.553-557.
  58. Daumerie, C. and Henquin, J.C., 1982. Acute effects of guar gum on glucose tolerance and intestinal absorption of nutrients in rats. Diabete & metabolisme, 8(1), p.1.
  59. Kapoor, M.P., Ishihara, N. and Okubo, T., 2016. Soluble dietary fibre partially hydrolysed guar gum markedly impacts on postprandial hyperglycaemia, hyperlipidaemia and incretins metabolic hormones over time in healthy and glucose intolerant subjects. Journal of Functional Foods, 24, pp.207-220.
  60. Arnold, S.V., Lipska, K.J., Li, Y., McGuire, D.K., Goyal, A., Spertus, J.A. and Kosiborod, M., 2014. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. American heart journal, 168(4), pp.466-470.
  61. Monickaraj, F., Aravind, S., Gokulakrishnan, K., Sathishkumar, C., Prabu, P., Prabu, D., Mohan, V. and Balasubramanyam, M., 2012. Accelerated aging as evidenced by increased telomere shortening and mitochondrial DNA depletion in patients with type 2 diabetes. Molecular and cellular biochemistry, 365(1-2), pp.343-350.
  62. Lin, H.J., Lee, B.C., Ho, Y.L., Lin, Y.H., Chen, C.Y., Hsu, H.C., Lin, M.S., Chien, K.L. and Chen, M.F., 2009. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. Diabetes Care, 32(9), pp.1721-1726.
  63. Mah, E., Noh, S.K., Ballard, K.D., Matos, M.E., Volek, J.S. and Bruno, R.S., 2011. Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine: arginine. The Journal of nutrition, 141(11), pp.1961-1968.
  64. Basa, A.L. and Garber, A.J., 2001. Cardiovascular disease and diabetes: Modifying risk factors other than glucose control. Ochsner Journal, 3(3), pp.132-137.
  65. Pepine, C.J., 2009. The impact of nitric oxide in cardiovascular medicine: untapped potential utility. The American journal of medicine, 122(5), pp.S10-S15.
  66. Cherbuin, N., Sachdev, P. and Anstey, K.J., 2012. Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study. Neurology, 79(10), pp.1019-1026.
  67. Ceriello, A. (2003). “The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications.” Diabetologia 46.
  68. Hirakawa, Y., Ninomiya, T., Mukai, N., Doi, Y., Hata, J., Fukuhara, M., Iwase, M., Kitazono, T. and Kiyohara, Y., 2012. Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study. American journal of epidemiology, 176(10), pp.856-864.
  69. Estébanez, N., Gómez-Acebo, I., Palazuelos, C., Llorca, J. and Dierssen-Sotos, T., 2018. Vitamin D exposure and Risk of Breast Cancer: a meta-analysis. Scientific reports, 8(1), pp.1-13.
  70. Dreosti, I.E., 1995. Magnesium status and health. Nutrition reviews, 53(9), p.S23.
  71. Kumar, R., Singh, A.K., Kumar, M., Shekhar, S., Rai, N., Kaur, P., Parshad, R. and Dey, S., 2016. Serum 5-LOX: a progressive protein marker for breast cancer and new approach for therapeutic target. Carcinogenesis, 37(9), pp.912-917.
  72. Bullmore, E., 2018. The inflamed mind: a radical new approach to depression. Picador.
  73. Guertin, D.A. and Sabatini, D.M., 2007. Defining the role of mTOR in cancer. Cancer cell, 12(1), pp.9-22.
  74. Guertin, D.A. and Sabatini, D.M., 2005. An expanding role for mTOR in cancer. Trends in molecular medicine, 11(8), pp.353-361.
  75. DeBerardinis, R.J. and Chandel, N.S., 2020. We need to talk about the Warburg effect. Nature metabolism, 2(2), pp.127-129.
  76. Wu, W.T., Cheng, H.C. and Chen, H.L., 2011. Ameliorative effects of konjac glucomannan on human faecal β-glucuronidase activity, secondary bile acid levels and faecal water toxicity towards Caco-2 cells. British journal of nutrition, 105(4), pp.593-600.
  77. Najjar, S., Pearlman, D.M., Alper, K., Najjar, A. and Devinsky, O., 2013. Neuroinflammation and psychiatric illness. Journal of neuroinflammation, 10(1), pp.1-24.
  78. Chang, C.Y., Ke, D.S. and Chen, J.Y., 2009. Essential fatty acids and human brain. Acta Neurol Taiwan, 18(4), pp.231-41.
  79. Singh, M., 2005. Essential fatty acids, DHA and human brain. The Indian Journal of Pediatrics, 72(3), pp.239-242.
  80. O’Brien, J.S. and Sampson, E.L., 1965. Lipid composition of the normal human brain: gray matter, white matter, and myelin. Journal of lipid research, 6(4), pp.537-544.
  81. Barth, C., Lonning, V., Gurholt, T.P., Andreassen, O.A., Myhre, A.M. and Agartz, I., 2020. Exploring white matter microstructure and the impact of antipsychotics in adolescent-onset psychosis. PloS one, 15(5), p.e0233684.
  82. Spillmann, M.K., Van der Does, A.W., Rankin, M.A., Vuolo, R.D., Alpert, J.E., Nierenberg, A.A., Rosenbaum, J.F., Hayden, D., Schoenfeld, D. and Fava, M., 2001. Tryptophan depletion in SSRI-recovered depressed outpatients. Psychopharmacology, 155(2), pp.123-127.
  83. Iodine deficiency. https://thyroidfoundation.org.au/
  84. Hynes, K.L., Otahal, P., Hay, I. and Burgess, J.R., 2013. Mild iodine deficiency during pregnancy is associated with reduced educational outcomes in the offspring: 9-year follow-up of the gestational iodine cohort. The Journal of Clinical Endocrinology & Metabolism, 98(5), pp.1954-1962.
  85. Velasco, I., Bath, S.C. and Rayman, M.P., 2018. Iodine as essential nutrient during the first 1000 days of life. Nutrients, 10(3), p.290.
  86. Ross, R.G., Hunter, S.K., McCarthy, L., Beuler, J., Hutchison, A.K., Wagner, B.D., Leonard, S., Stevens, K.E. and Freedman, R., 2013. Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk. American Journal of Psychiatry, 170(3), pp.290-298.
  87. Sankowski, R., Mader, S. and Valdés-Ferrer, S.I., 2015. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Frontiers in cellular neuroscience, 9, p.28.
  88. Morris, G., Fernandes, B.S., Puri, B.K., Walker, A.J., Carvalho, A.F. and Berk, M., 2018. Leaky brain in neurological and psychiatric disorders: drivers and consequences. Australian & New Zealand Journal of Psychiatry, 52(10), pp.924-948.
  89. Daneman, R. and Rescigno, M., 2009. The gut immune barrier and the blood-brain barrier: are they so different?. Immunity, 31(5), pp.722-735.
  90. Type-3 Diabetes (Diabetes of the Brain). https://diabetesnsw.com.au/about-us/blog/what-is-type-3-diabetes/
  91. Rasgon, N.L. and McEwen, B.S., 2016. Insulin resistance—a missing link no more. Molecular psychiatry, 21(12), pp.1648-1652.
  92. Liu, G., Weinger, J.G., Lu, Z.L., Xue, F. and Sadeghpour, S., 2016. Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial. Journal of Alzheimer’s Disease, 49(4), pp.971-990.
  93. Gommers, L.M., Hoenderop, J.G., Bindels, R.J. and de Baaij, J.H., 2016. Hypomagnesemia in type 2 diabetes: a vicious circle?. Diabetes, 65(1), pp.3-13.
  94. Baghurst, K.I., Dreosti, I.E., Syrette, J.A., Record, S.J., Baghurst, P.A. and Buckley, R.A., 1991. Zinc and magnesium status of Australian adults. Nutrition research, 11(1), pp.23-32.
  95. Ridaura, V. and Belkaid, Y., 2015. Gut microbiota: the link to your second brain. Cell, 161(2), pp.193-194.
  96. Kim, D.Y. and Camilleri, M., 2000. Serotonin: a mediator of the brain-gut connection. The American journal of gastroenterology, 95(10), p.2698.
  97. Tracey, K.J., 2002. The inflammatory reflex. Nature, 420(6917), pp.853-859.
  98. https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/
  99. Wallace, T.C., Blusztajn, J.K., Caudill, M.A., Klatt, K.C., Natker, E., Zeisel, S.H. and Zelman, K.M., 2018. Choline: The underconsumed and underappreciated essential nutrient. Nutrition today, 53(6), p.240.
  100. Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H. and Häring, H.U., 2016. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiological reviews.
  101. Volpi, E., Kobayashi, H., Sheffield-Moore, M., Mittendorfer, B. and Wolfe, R.R., 2003. Essential amino acids are primarily responsible for the amino acid stimulation of muscle protein anabolism in healthy elderly adults. The American journal of clinical nutrition, 78(2), pp.250-258.
  102. Jonker, R., Engelen, M.P. and Deutz, N.E., 2012. Role of specific dietary amino acids in clinical conditions. British Journal of Nutrition, 108(S2), pp.S139-S148.
  103. Romano, C., Corsetti, G., Flati, V., Pasini, E., Picca, A., Calvani, R., Marzetti, E. and Dioguardi, F.S., 2019. Influence of diets with varying essential/nonessential amino acid ratios on mouse lifespan. Nutrients, 11(6), p.1367.
  104. Doherty, T.J., 2003. Invited review: aging and sarcopenia. Journal of applied physiology.
  105. Baik, H.W. and Russell, R.M., 1999. Vitamin B12 deficiency in the elderly. Annual review of nutrition, 19(1), pp.357-377.
  106. Norton, L. and G. J. Wilson (2009). “Optimal protein intake to maximize muscle protein synthesis.” AgroFood industry hi-tech 20: 54-57.
  107. Zhao, X., Han, Q., Liu, Y., Sun, C., Gang, X. and Wang, G., 2016. The relationship between branched-chain amino acid related metabolomic signature and insulin resistance: a systematic review. Journal of diabetes research, 2016.
  108. Kris-Etherton, P., Eckel, R.H., Howard, B.V., St. Jeor, S. and Bazzarre, T.L., 2001. Lyon diet heart study: benefits of a Mediterranean-Style, National Cholesterol Education Program/American Heart Association Step I dietary pattern on cardiovascular disease. Circulation, 103(13), pp.1823-1825.
  109. DuBroff, R. and de Lorgeril, M., 2015. Cholesterol confusion and statin controversy. World journal of cardiology, 7(7), p.404.
  110. Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., Kuder, J.F., Wang, H., Liu, T., Wasserman, S.M. and Sever, P.S., 2017. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376(18), pp.1713-1722.
  111. Ross, S.D., Allen, I.E., Connelly, J.E., Korenblat, B.M., Smith, M.E., Bishop, D. and Luo, D., 1999. Clinical outcomes in statin treatment trials: a meta-analysis. Archives of internal medicine, 159(15), pp.1793-1802.
  112. DuBroff, R., 2018. A reappraisal of the lipid hypothesis. The American journal of medicine, 131(9), pp.993-997.
  113. Wise, J., 2017. Long term study backs statins for patients with high LDL and no other risk factors.
  114. Batty, G., Kivimäki, M., Smith, G. D., Marmot, M., & Shipley, M. (2008). Post-challenge blood glucose concentration and stroke mortality rates in nondiabetic men in London: 38-year follow-up of the original Whitehall prospective cohort study.
  115. Muti, P., Quattrin, T., Grant, B.J., Krogh, V., Micheli, A., Schünemann, H.J., Ram, M., Freudenheim, J.L., Sieri, S., Trevisan, M. and Berrino, F., 2002. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiology and Prevention Biomarkers, 11(11), pp.1361-1368.
  116. DuBroff, R., 2017. Cholesterol paradox: a correlate does not a surrogate make. BMJ Evidence-Based Medicine, 22(1), pp.15-19.
  117. Grønholdt, M.L.M., Nordestgaard, B.G., Nielsen, T.G. and Sillesen, H., 1996. Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke, 27(12), pp.2166-2172.

Dr. Rodney Lopez

MBBS (Usyd) GradCertNutriMed (RMIT)

We value feedback and suggestion. We also welcome Allied Health and Medical Practitioners to join our nutrition-focused team. Please contact us

Contact Us Find a Practitioner Product Queries Disclaimer